SLCO1B1 Variants and Statin-Induced Myopathy — A Genomewide Study

Cited by (1,002)

Items 501–600 of 1,002

1. Pharmacogenetic Foundations of Therapeutic Efficacy and Adverse Events of Statins
   Elena Arrigoni, Marzia Del Re, Leonardo Fidilio, Stefano Fogli, Romano Danesi, Antonello Di Paolo · 2017 · International Journal of Molecular Sciences
2. Utilization of OATP1B Biomarker Coproporphyrin‐I to Guide Drug–Drug Interaction Risk Assessment: Evaluation by the Pharmaceutical Industry
   Ryota Kikuchi, Paresh P. Chothe, Xiaoyan Chu, Felix Huth, Kazuya Ishida, Naoki Ishiguro, Rongrong Jiang, Hong Shen, Simone H. Stahl, Manthena V. S. Varma et al. · 2023 · Clinical Pharmacology & Therapeutics
3. Statins as anti‐tumor agents: A paradigm for repurposed drugs
   Sneha Tripathi, Ekta Gupta, Sanjeev Galande · 2024 · Cancer Reports
4. Can statins prevent pregnancy complications?
   Guillermina Girardi · 2013 · Journal of Reproductive Immunology
5. Statin induced necrotizing autoimmune myopathy
   Suma Babu, Yuebing Li · 2015 · Journal of the Neurological Sciences
6. Increased autophagy accelerates colchicine-induced muscle toxicity
   James Kain Ching, Jeong-Sun Ju, Sara K. Pittman, Marta Margeta, Conrad C. Weihl · 2013 · Autophagy
7. Data-Driven Methods to Discover Molecular Determinants of Serious Adverse Drug Events
   Annie Pei-Fen Chiang, Atul Janardhan Butte · 2009 · Clinical Pharmacology & Therapeutics
8. The pharmacogenomics of statins
   Ingrid C. Gelissen, Andrew J. McLachlan · 2013 · Pharmacological Research
9. Patients experiencing statin-induced myalgia exhibit a unique program of skeletal muscle gene expression following statin re-challenge
   Marshall B. Elam, Gipsy Majumdar, Khyobeni Mozhui, Ivan Gerling, SANTIAGO R. VERA, Hannah L. Fish-Trotter, Robert W. Williams, Richard Dale Childress, Rajendra Raghow · 2017 · PLoS ONE
10. Individualized care for portal hypertension: Not quite yet
    Patrick S. Kamath, Rajeshwar P. Mookerjee · 2015 · Journal of Hepatology
11. Organic anion transporting polypeptides: Pharmacology, toxicology, structure, and transport mechanisms
    Bruno Hagenbuch, Bruno Stieger, Kaspar P. Locher · 2024 · Pharmacological Reviews
12. Pharmacogenetic Interactions Between ABCB1 and SLCO1B1 Tagging SNPs and the Effectiveness of Statins in the Prevention of Myocardial Infarction
    Bas J.M. Peters, Andréi S. Rodin, Olaf H. Klungel, Cornelia M. van Duijn, Bruno H. Ch. Stricker, Ruben van ‘t Slot, Anthonius de Boer, Anke H. Maitland‐van der Zee · 2010 · Pharmacogenomics
13. An Updated Review of Genetic Associations With Severe Adverse Drug Reactions: Translation and Implementation of Pharmacogenomic Testing in Clinical Practice
    Chuang‐Wei Wang, Ivan Arni C. Preclaro, Wei-Hsiang Lin, Wen‐Hung Chung · 2022 · Frontiers in Pharmacology
14. Artificial intelligence, nano-technology and genomic medicine: The future of anaesthesia
    Shagufta Naaz, Adil Asghar · 2022 · Journal of Anaesthesiology Clinical Pharmacology
15. Preventability of Drug-Related Harms – Part II
    Jeffrey K Aronson, Robin Esmond Ferner · 2010 · Drug Safety
16. Translational insight into statin-induced muscle toxicity: from cell culture to clinical studies
    Dhiaa A. Taha, Cornelia H. de Moor, David A. Barrett, Pavel Gershkovich · 2014 · Translational research
17. Transporters in drug development: advancing on the Critical Path
    Shiew Mei Huang, Janet Woodcock · 2010 · Nature Reviews Drug Discovery
18. Pharmacogenetics of Statins: Achievements, Whole-genome Analyses and Future Perspectives
    Iris Postmus, Jeffrey J. W. Verschuren, Anton J.M. de Craen, P. Eline Slagboom, Rudi G. J. Westendorp, J. Wouter Jukema, Stella Trompet · 2012 · Pharmacogenomics
19. Statins and muscle pain
    Joseph V. Pergolizzi, Flaminia Coluzzi, Robert D. Colucci, Hanna Olsson, Jo Ann LeQuang, Jonathan Al‐Saadi, Peter Magnusson · 2020 · Expert Review of Clinical Pharmacology
20. Independent risk factors for simvastatin-related myopathy and relevance to different types of muscle symptom
    Jemma C. Hopewell, Alison R. Offer, Richard Haynes, Louise J. Bowman, Jing Li, Fang Chen, Richard A. Bulbulia, Mark G. Lathrop, Colin Baigent, Martin Landray et al. · 2020 · European Heart Journal
21. A systematic review and meta-analysis of genotype-based and individualized data analysis of SLCO1B1 gene and statin-induced myopathy
    Saowalak Turongkaravee, Jiraphun Jittikoon, Thitiya Lukkunaprasit, Sermsiri Sangroongruangsri, Usa Chaikledkaew, Ammarin Thakkinstian · 2021 · The Pharmacogenomics Journal
22. Performance of Plasma Coproporphyrin I and III as OATP1B1 Biomarkers in Humans
    Mikko Neuvonen, Aleksi Tornio, Päivi Hirvensalo, Janne T. Backman, Mikko Niemi · 2021 · Clinical Pharmacology & Therapeutics
23. Genomewide Association Study of Simvastatin Pharmacokinetics
    Anssi J. H. Mykkänen, Suvi Taskinen, Mikko Neuvonen, Maria Paile‐Hyvärinen, E. Katriina Tarkiainen, Tuomas Olavi Lilius, Tuija Tapaninen, Janne T. Backman, Aleksi Tornio, Mikko Niemi · 2022 · Clinical Pharmacology & Therapeutics
24. The Future of Biomarkers in Veterinary Medicine: Emerging Approaches and Associated Challenges
    Tharangani R. W. Perera, David Anthony Skerrett-Byrne, Zamira Gibb, Brett Nixon, Aleona Swegen · 2022 · Animals
25. Host genetics and parasitic infections
    Valentina Dianora Mangano, David Modiano · 2014 · Clinical Microbiology and Infection
26. The role of vitamin D and SLCO1B1 gene polymorphism in statin-associated myalgias
    Randy Linde, Lihong Peng, Manisha Desai, David Feldman · 2010 · Dermato-Endocrinology
27. En route to precision medicine through the integration of biological sex into pharmacogenomics
    Lea Gaignebet, Georgios Kararigas · 2017 · Clinical Science
28. SLCO1B1 521T > C polymorphism associated with rosuvastatin-induced myotoxicity in Chinese coronary artery disease patients: a nested case–control study
    Jue Liu, Xiaoying Liu, Sheng Chen, Yan Zhang, Liyun Cai, Min Yang, Weihua Lai, Bin Ren, Shilong Zhong · 2017 · European Journal of Clinical Pharmacology
29. Generating evidence for precision medicine: considerations made by the Ubiquitous Pharmacogenomics Consortium when designing and operationalizing the PREPARE study
    Cathelijne H. van der Wouden, Stefan Böhringer, Erika Cecchin, Ka-Chun Cheung, Cristina Lucía Dávila-Fajardo, Vera H.M. Deneer, Vita Dolžan, Magnus Ingelman‐Sundberg, Siv Jönsson, Mats O. Karlsson et al. · 2020 · Pharmacogenetics and Genomics
30. Effect of SLCO1B1 Polymorphisms on High‐Dose Methotrexate Clearance in Children and Young Adults With Leukemia and Lymphoblastic Lymphoma
    Rachael R. Schulte, Leena Choi, Nipun Utreja, Sara L. Van Driest, Christoph Stein, Richard H. Ho · 2020 · Clinical and Translational Science
31. Recent Clinical Studies of the Effects of Lipid-Modifying Therapies
    Antonio M. Gotto, Jennifer E. Moon · 2012 · The American Journal of Cardiology
32. Thiazide‐Induced Hyponatraemia: Epidemiology and Clues to Pathogenesis
    Mark Glover, Jenny Clayton · 2011 · Cardiovascular Therapeutics
33. Interaction of fluvastatin with the liver-specific Na+-dependent taurocholate cotransporting polypeptide (NTCP)
    Rick Greupink, Lieve Dillen, Mario Monshouwer, Maarten T. Huisman, Frans G. M. Rüssel · 2011 · European Journal of Pharmaceutical Sciences
34. GATM Polymorphism Associated with the Risk for Statin-Induced Myopathy Does Not Replicate in Case-Control Analysis of 715 Dyslipidemic Individuals
    Jasmine A. Luzum, Joseph P. Kitzmiller, Paul J. Isackson, Chang‐Xing Ma, Marisa Wong Medina, Anees M. Dauki, Eduard Mikulik, Heather M. Ochs‐Balcom, Georgirene D. Vladutiu · 2015 · Cell Metabolism
35. Developmental pharmacogenomics
    Kathleen A. Neville, Mara L. Becker, Jennifer L. Goldman, Gregory L. Kearns · 2011 · Pediatric Anesthesia
36. Cardiovascular pharmacogenetics: a promise for genomically‐guided therapy and personalized medicine
    Mohamed Zaiou, Hamid El Amri · 2016 · Clinical Genetics
37. Recommendations for Managing Drug–Drug Interactions with Statins and HIV Medications
    Barbara S. Wiggins, Donald G. Lamprecht, Robert Lee Page II, Joseph J. Saseen · 2017 · American Journal of Cardiovascular Drugs
38. Assessment of the Risk of Rhabdomyolysis and Myopathy During Concomitant Treatment with Ticagrelor and Statins
    Dorota Danielak, Marta Karaźniewicz‐Łada, Franciszek Krzysztof Główka · 2018 · Drugs
39. Toxic Myopathies
    Christopher T. Doughty, Anthony A. Amato · 2019 · CONTINUUM Lifelong Learning in Neurology
40. Interaction of Macrolide Antibiotics with Intestinally Expressed Human and Rat Organic Anion-Transporting Polypeptides
    Tian Lan, Anuradha Rao, Jamie Haywood, Charles B. Davis, Chao Han, Eric M. Garver, Paul A. Dawson · 2009 · Drug Metabolism and Disposition
41. Evaluation of Organic Anion Transporting Polypeptide 1B1 and 1B3 Humanized Mice as a Translational Model to Study the Pharmacokinetics of Statins
    Laurent Salphati, Xiaoyan Chu, Liangfu Chen, Bhagwat Prasad, Shannon Dallas, Raymond Evers, Donna Mamaril-Fishman, Ethan G. Geier, Jonathan R. Kehler, Jeevan R. Kunta et al. · 2014 · Drug Metabolism and Disposition
42. Pharmacogenomics and Stratified Medicine
    Sandosh Padmanabhan · 2014 · Elsevier eBooks
43. Why, When, and How Should Pharmacogenetics Be Applied in Clinical Studies?: Current and Future Approaches to Study Designs
    Julia Kirchheiner, Jürgen Brockmöller · 2011 · Clinical Pharmacology & Therapeutics
44. Genetic variation in the ABCC2 gene is associated with dose decreases or switches to other cholesterol-lowering drugs during simvastatin and atorvastatin therapy
    Matthijs L. Becker, Laure Elens, Loes E. Visser, Albert Hofman D, André Gerardus Uitterlinden, Ron H. N. van Schaik, Bruno H. Ch. Stricker · 2011 · The Pharmacogenomics Journal
45. SLCO1B1Polymorphism and Oral Antidiabetic Drugs
    Annikka Kalliokoski, Pertti J. Neuvonen, Mikko Niemi · 2010 · Basic & Clinical Pharmacology & Toxicology
46. Whole-Genome Sequencing in Personalized Therapeutics
    Pablo Cordero, Euan Angus Ashley · 2012 · Clinical Pharmacology & Therapeutics
47. Pharmacogenetics in cardiovascular diseases: State of the art and implementation-recommendations of the French National Network of Pharmacogenetics (RNPGx)
    Fabien Lamoureux, Thomas Duflot · 2017 · Therapies
48. Impact ofSLCO1B1Genotype on Pediatric Simvastatin Acid Pharmacokinetics
    Jonathan B. Wagner, Susan M. Abdel‐Rahman, Leon van Haandel, Andrea Gaedigk, Roger Gaedigk, Geetha Raghuveer, Ralph E. Kauffman, James Steven Leeder · 2018 · The Journal of Clinical Pharmacology
49. Statin-Induced Myopathy: Translational Studies from Preclinical to Clinical Evidence
    Giulia Maria Camerino, Nancy Tarantino, Ileana Canfora, Michela De Bellis, Olimpia Musumeci, Sabata Pierno · 2021 · International Journal of Molecular Sciences
50. Genome-wide association study for type 2 diabetes: clinical applications
    Valeriya Lyssenko, Leif Groop · 2009 · Current Opinion in Lipidology
51. MicroRNA-26a-5p inhibits proliferation, invasion and metastasis by repressing the expression of Wnt5a in papillary thyroid carcinoma
    Dongliang Shi, Haiyan Wang, Mingjian Ding, Meng Yang, Chenhao Li, Wenhua Yang, Liang Chen · 2019 · OncoTargets and Therapy
52. Genotype-based clinical trials in cardiovascular disease
    Naveen L. Pereira, Daniel J. Sargent, Michael E. Farkouh, Charanjit S. Rihal · 2015 · Nature Reviews Cardiology
53. Integration of Genomics in Primary Care
    Eric A. Larson, Russell A. Wilke · 2015 · The American Journal of Medicine
54. Emerging Genomic Applications in Coronary Artery Disease
    Samir B. Damani, Eric J. Topol · 2011 · JACC: Cardiovascular Interventions
55. Association of common variants in the human eyes shut ortholog (EYS) with statin‐induced myopathy: Evidence for additional functions of EYS
    Paul J. Isackson, Heather M. Ochs‐Balcom, Chang‐Xing Ma, John B. Harley, Wendy Peltier, Mark Andrew Tarnopolsky, Naganand Sripathi, Robert L. Wortmann, Zachary Simmons, Jon D. Wilson et al. · 2011 · Muscle & Nerve
56. Regionally clustered ABCC8 polymorphisms in a prospective cohort predict cerebral oedema and outcome in severe traumatic brain injury
    Ruchira Menka Jha, Theresa A. Koleck, Ava M. Puccio, David O. Okonkwo, Seo‐Young Park, Benjamin E. Zusman, Robert S. B. Clark, Lori Shutter, Jessica S. Wallisch, Philip E. Empey et al. · 2018 · Journal of Neurology Neurosurgery & Psychiatry
57. Efficacy and safety of rosuvastatin in the management of dyslipidemia
    Paolo Rubba · 2009 · Vascular Health and Risk Management
58. Muscle toxicity with statins
    Karin Hedenmalm, Gunnar Alván, Patrik Öhagen, Marja­‐Liisa Dahl · 2009 · Pharmacoepidemiology and Drug Safety
59. Statins Personalized
    H. Robert Superko, Kathryn M. Momary, Yonghong Li · 2012 · Medical Clinics of North America
60. Perspectives on low-density-lipoprotein cholesterol goal achievement
    Catapano, Alberico L. · 2009 · Current Medical Research and Opinion
61. The Farnesoid X Receptor as a Master Regulator of Hepatotoxicity
    Magdalena Rausch, Sophia L. Samodelov, Michele Visentin, Gerd Achim Kullak-Ublick · 2022 · International Journal of Molecular Sciences
62. Whole genome association studies in complex diseases: where do we stand?
    Anna C. Need, David B. Goldstein · 2010 · Dialogues in Clinical Neuroscience
63. ABCG2 Gene Polymorphisms as Risk Factors for Atorvastatin Adverse Reactions: A Case–Control Study
    Nikica Mirošević Skvrce, Viola Macolić Šarinić, Iveta Šimić, Lana Ganoci, Diana Muačević Katanec, Nada Božina · 2015 · Pharmacogenomics
64. Statin Therapy and the Expression of Genes that Regulate Calcium Homeostasis and Membrane Repair in Skeletal Muscle
    Annette Draeger, Verónica Sánchez-Freire, Katia Monastyrskaya, Hans H. Hoppeler, Matthias Mueller, Fabio Breil, Markus Georg Mohaupt, Eduard B. Babiychuk · 2010 · American Journal Of Pathology
65. Drug interactions with statins
    Anida Čaušević-Ramoševac, Sabina Semiz · 2013 · Acta Pharmaceutica
66. Expanding Role of Pharmacogenomics in the Management of Cardiovascular Disorders
    Vincent Lai Ming Yip, Munir Pirmohamed · 2013 · American Journal of Cardiovascular Drugs
67. Variability in hepatic expression of organic anion transporter 7/SLC22A9, a novel pravastatin uptake transporter: impact of genetic and regulatory factors
    Arian Emami Riedmaier, Oliver Burk, Barbara A. C. van Eijck, Elke Schaeffeler, Kathrin Klein, Sarah Fehr, Saskia Biskup, S Müller, Stefan Winter, Ulrich M. Zanger et al. · 2015 · The Pharmacogenomics Journal
68. Early high-dose lipid-lowering therapy to avoid cardiac events: a systematic review and economic evaluation
    Roberta Ara, Abdullah Pandor, John Stevens, Angie Rees, Rachid Rafia · 2009 · Health Technology Assessment
69. Genetic and immunologic susceptibility to statin-related myopathy
    Jaideep Patel, H. Robert Superko, Seth Shay Martin, Roger Scott Blumenthal, Lisa Christopher‐Stine · 2015 · Atherosclerosis
70. Recent advances: personalised use of current Crohn's disease therapeutic options
    Séverine Vermeire, Marc Ferrante, Paul J. Rutgeerts · 2013 · Gut
71. PDZK1 binding and serine phosphorylation regulate subcellular trafficking of organic anion transport protein 1a1
    Jo H. Choi, John W. Murray, Allan W. Wolkoff · 2010 · American Journal of Physiology-Gastrointestinal and Liver Physiology
72. Current status of biomarker research in neurology
    Jiří Polívka, Jiří Polívka, Kristýna Krakorová, Marek Peterka, Ondřej Topolčan · 2016 · The EPMA Journal
73. A Double‐Blind , Randomized, Controlled Trial of Lovastatin in Early‐Stage Parkinson's Disease
    Chin‐Hsien Lin, Chin‐Hao Chang, Chun‐Hwei Tai, Mei‐Fang Cheng, Yi‐Chieh Chen, Ying‐Ting Chao, Tse‐Le Huang, Ruoh‐Fang Yen, Ruey‐Meei Wu · 2021 · Movement Disorders
74. In Silico Classification of Major Clearance Pathways of Drugs with Their Physiochemical Parameters
    Makiko Kusama, Kouta Toshimoto, Kazuya Maeda, Yuka Hirai, Satoki Imai, Kōji Chiba, Yutaka Akiyama, Yuichi Sugiyama · 2010 · Drug Metabolism and Disposition
75. Pharmacogenetics of Idiosyncratic Adverse Drug Reactions
    Munir Pirmohamed · 2009 · Handbook of experimental pharmacology
76. Are statins really wonder drugs?
    Harpreet Singh Grover, Shailly Luthra, Shruti Maroo · 2013 · Journal of the Formosan Medical Association
77. Overview of Green Tea Interaction with Cardiovascular Drugs
    José Pablo Werba, Shingen Misaka, Monica Giroli, Shizuo Yamada, Viviana Cavalca, Keisuke Kawabe, Isabella Squellerio, Federica Laguzzi, Satomi Onoue, Fabrizio Veglia et al. · 2014 · Current Pharmaceutical Design
78. Contribution of Hepatic Organic Anion-Transporting Polypeptides to Docetaxel Uptake and Clearance
    Hannah H. Lee, Brenda F. Leake, Wendy A. Teft, Rommel G. Tirona, Richard B. Kim, Richard H. Ho · 2015 · Molecular Cancer Therapeutics
79. Downregulation of Organic Anion Transporting Polypeptide (OATP) 1B1 Transport Function by Lysosomotropic Drug Chloroquine: Implication in OATP-Mediated Drug-Drug Interactions
    Khondoker Alam, Sonia Pahwa, Xueying Wang, Pengyue Zhang, Kai Ding, Alaa H. Abuznait, Lang Li, Wei Yue · 2016 · Molecular Pharmaceutics
80. A Pharmacometabonomic Approach To Predicting Metabolic Phenotypes and Pharmacokinetic Parameters of Atorvastatin in Healthy Volunteers
    Qing Bo Huang, Jiye Aa, Huning Jia, Xiaoqing Xin, Chunlei Tao, Linsheng Liu, Bingjie Zou, Qinxin Song, Jian Shi, Bei Cao et al. · 2015 · Journal of Proteome Research
81. Association between SLCO1B1 −521T>C and −388A>G polymorphisms and risk of statin-induced adverse drug reactions: A meta-analysis
    Jiajia Jiang, Qing Tang, Jing Feng, Rong Dai, Yang Wang, Yuan Yang, Xiaojun Tang, Changkai Deng, Huan Zeng, Yong Zhao et al. · 2016 · SpringerPlus
82. Statin-associated muscle symptoms: position paper from the Luso-Latin American Consortium
    Andrei Carvalho Sposito, José Rocha Faria‐Neto, Luiz Sérgio Fernandes de Carvalho, Alberto J. Lorenzatti, Alberto Cafferata, Gerardo D. Elikir, Eduardo Esteban, Enrique C. Morales Villegas, Luiz Carlos Bodanese, Rodrigo Alonso K et al. · 2016 · Current Medical Research and Opinion
83. Precision medicine and pharmacogenetics: what does oncology have that addiction medicine does not?
    Henry R. Kranzler, Rachel Vickers‐Smith, Robert A. Schnoll, Afaf F. Moustafa, Emma Greenstreet Akman · 2017 · Addiction
84. Drug-Induced Rhabdomyolysis Atlas (DIRA) for idiosyncratic adverse drug reaction management
    Zhining Wen, Liang Yu, Yingyi Hao, Brian Delavan, Ruili Huang, Mike Mikailov, Weida Tong, Menglong Li, Zhichao Liu · 2018 · Drug Discovery Today
85. Cost-Effectiveness of Multigene Pharmacogenetic Testing in Patients With Acute Coronary Syndrome After Percutaneous Coronary Intervention
    Olivia M Dong, Stephanie B. Wheeler, Gracelyn Cruden, Craig R. Lee, Deepak Voora, Stacie B. Dusetzina, Tim Wiltshire · 2019 · Value in Health
86. Phase I/IIa Trial of Atorvastatin in Patients with Acute Kawasaki Disease with Coronary Artery Aneurysm
    Adriana H. Tremoulet, Sonia Jain, Pei‐Ni Jone, Brookie M. Best, Elizabeth Duxbury, Alessandra Franco, Beth Feller Printz, Samuel R. Dominguez, Heather R. Heizer, Marsha S. Anderson et al. · 2019 · The Journal of Pediatrics
87. Safety and efficacy of the addition of simvastatin to cetuximab in previously treated KRAS mutant metastatic colorectal cancer patients
    Jara M. Baas, Lisanne L. Krens, Albert J. ten Tije, Frans Erdkamp, Tom van Wezel, Hans Morreau, Hans A. J. Gelderblom, Henk‐Jan Guchelaar · 2015 · Investigational New Drugs
88. ACE (I/D) polymorphism and response to treatment in coronary artery disease: a comprehensive database and meta-analysis involving study quality evaluation
    Georgios D. Kitsios, Elias Zintzaras · 2009 · BMC Medical Genetics
89. Pharmacogenetics of Drug Transporters in the Enterohepatic Circulation
    Bruno Stieger, Peter J. Meier · 2011 · Pharmacogenomics
90. Impact of CYP2D6, CYP3A5, CYP2C19, CYP2A6, SLCO1B1, ABCB1, and ABCG2 gene polymorphisms on the pharmacokinetics of simvastatin and simvastatin acid
    Choi, Hee Youn, Bae, Kyun-Seop, Cho, Sang-Heon, Ghim, Jong-Lyul, Choe, Sangmin, Jung, Jin Ah, Jin, Seok-Joon, Kim, Hee-Sun, Lim, Hyeong-Seok · 2015 · Pharmacogenetics and Genomics
91. The Role of Transporters in Toxicity and Disease
    John D. Schuetz, Peter W. Swaan, Donald Tweedie · 2014 · Drug Metabolism and Disposition
92. Personalized cardiovascular medicine: concepts and methodological considerations
    Henry Völzke, Carsten Oliver Schmidt, Sebastian Edgar Baumeister, Till Ittermann, Glenn Fung, Janina Krafczyk-Korth, Wolfgang U. Hoffmann, Matthias Georg Schwab, Henriette E. Meyer zu Schwabedissen, Marcus Dörr et al. · 2013 · Nature Reviews Cardiology
93. Delivering pharmacogenetic testing in a primary care setting
    Rachel A. Mills, Deepak Voora, Bruce Peyser, Susanne B. Haga · 2013 · Pharmacogenomics and Personalized Medicine
94. Pharmacogenomics and personalized medicine: wicked problems, ragged edges and ethical precipices
    Leonard Michael Fleck · 2012 · New Biotechnology
95. Mapping Genes that Predict Treatment Outcome in Admixed Populations
    T. Baye, R. A. Wilke · 2010 · The Pharmacogenomics Journal
96. Pharmacogenomics of G Protein-Coupled Receptor Ligands in Cardiovascular Medicine
    Dieter Rosskopf, Martin Christian Michel · 2008 · Pharmacological Reviews
97. Pharmabiotics as an Emerging Medication for Metabolic Syndrome and Its Related Diseases
    Thị Thanh Bình Nguyễn, Yan Jin, Hea‐Jong Chung · 2017 · Molecules
98. An update on efflux and uptake transporters as determinants of statin response
    Karina Cunha e Rocha, Beatriz Maria Veloso Pereira, Alice Cristina Rodrigues · 2018 · Expert Opinion on Drug Metabolism & Toxicology
99. Opportunities and Challenges in Cardiovascular Pharmacogenomics
    Dan M. Roden, Sara L. Van Driest, Quinn Stanton Wells, Jonathan D. Mosley, Joshua C. Denny, Josh F. Peterson · 2018 · Circulation Research
100. Statin intolerance
     Ulrich Laufs, Hubert Scharnagl, Winfried März · 2015 · Current Opinion in Lipidology